Research Topics
Genomes and Genes | Ayalew TefferiSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
How to interpret and pursue an abnormal complete blood cell count in adultsAyalew Tefferi
Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 80:923-36. 2005..The objective is to help the nonhematologist recognize when a subspecialty consultation is reasonable and when it may be circumvented, thus allowing a cost-effective and intellectually rewarding practice...
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia veraAyalew Tefferi
Division of Hematology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, and Department of Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Cancer 106:631-5. 2006..Several studies have recently reported on the occurrence of a JAK2(V617F) mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study...
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophiliaAnimesh Pardanani
Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Blood 104:3038-45. 2004..In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis...
Lenalidomide therapy in myelofibrosis with myeloid metaplasiaAyalew Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Blood 108:1158-64. 2006..We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities...
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosineKen H Lim
Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 84:790-4. 2009....
Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlatesNaseema Gangat
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 80:197-200. 2008..02), but not JAK2V617F allele burden, thrombosis, hemorrhage, leukemic/fibrotic transformation, or survival. We conclude that cytogenetic anomalies occur infrequently at PV diagnosis and do not confer an adverse outcome...
Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlatesMrinal M Patnaik
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 84:518-24. 2010..The current study was designed to provide additional data in this regard...
Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocationsStephanie R Fink
Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
Leuk Res 33:843-6. 2009..Our results revealed this new FISH assay accurately detects these abnormalities and will be a useful clinical test for patients with myeloid neoplasms and eosinophilia...
Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide eraShernan G Holtan
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 83:708-13. 2008..Additional important prognostic factors not taken into account by the IPSS include the baseline erythrocyte indices, lymphocyte count, and clonal burden...
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemiaAyalew Tefferi
Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Br J Haematol 131:166-71. 2005..However, compared with the PRV-1 assay, mutation screening for JAK2(V617F) displayed greater accuracy in distinguishing PV from SP...
Clinical correlates of JAK2V617F allele burden in essential thrombocythemiaJaya Kittur
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 109:2279-84. 2007..A possible association with thrombotic complication has also been considered...
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over timeTerra L Lasho
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 135:683-7. 2006..We conclude that MPLW515L/K and JAK2V617F are both early events in MMM and allele burden, rather than the mere presence of these mutations, might be relevant to phenotypic variation in myeloproliferative disorders...
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion statusNaseema Gangat
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 29:392-7. 2011..The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status...
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevanceAlexandra P Wolanskyj
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 131:208-13. 2005..Therefore, although the presence of JAK2(V617F) in ET appears to promote a PV phenotype, it might not carry treatment-relevant information...
Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institutionMrinal M Patnaik
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Am J Hematol 85:238-42. 2010..We conclude that neither the SCLL phenotype nor blood eosinophilia is a consistent feature of FGFR1-associated 8p11.2 translocations; conversely, FISH might not always reveal FGFR1 involvement in typical SCLL...
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytesAnimesh Pardanani
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
Stem Cells 25:2358-62. 2007..These observations suggest that clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations and that the latter is acquired in a lympho-myeloid progenitor cell...
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyureaShireen Sirhan
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 83:363-5. 2008..02). The current study suggests that JAK2V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV...
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and managementAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 87:285-93. 2012..Treatment with busulfan or interferon-? is usually effective in hydroxyurea failures. Screening for clinically significant AvWS is recommended before administrating aspirin in the presence of extreme thrombocytosis...
Karyotype complements the International Prognostic Scoring System for primary myelofibrosisKebede Hussein
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 82:255-9. 2009..The presence of 0, 1, 2, and > or =3 adverse factors defines low, intermediate-1, intermediate-2, and high risk disease, respectively. We examined the additional prognostic relevance of karyotype...
The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlatesAyalew Tefferi
Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Br J Haematol 131:320-8. 2005....
Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative casesRafael Santana-Davila
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Leuk Res 32:1927-30. 2008..When used, lenalidomide therapy induced hematological and cytogenetic remissions in del(5q)-positive PMF. The current study identifies PMF as another del(5q)-associated myeloid malignancy with characteristic megakaryocyte morphology...
JAK2 in myeloproliferative disorders is not just another kinaseAyalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cell Cycle 4:1053-6. 2005..Taken together, these observations suggest that JAK2(V617F) is an acquired myeloid lineage-specific mutation that engenders a pathogenetic relevance for the PV phenotype in MPD...
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformationNaseema Gangat
Division of Hematology, Department of Medicine, Laboratory Medicine, and Health Sciences Research, Mayo Clinic, Rochester, MN, USA
Br J Haematol 138:354-8. 2007..The current study highlighted the prognostic relevance of leucocytosis on various aspects of the disease in PV...
Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapyAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 106:1739-43. 2006..For the current study, the authors explored the relation between specific cytogenetic clones and JAK2(V617F) mutational status in patients with MMM and the effects on treatment response to erythropoietin (Epo)...
Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent yearsRakhee Vaidya
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 84:1114-9. 2009..002), not in those with low-risk disease (P=.42). These observations are encouraging and suggest a salutary effect from modern therapeutic approaches in PMF...
20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosisAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 80:386-90. 2008....
Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patientsMrinal M Patnaik
Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 86:393-8. 2011....
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling studyAyalew Tefferi
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 29:1356-63. 2011..This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance...
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment updateAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 85:158-64. 2010..In the current review, we provide a simplified algorithm for distinguishing the various causes of clonal and idiopathic eosinophilia and discuss current therapy, including new drugs (imatinib mesylate, alemtuzumab, and mepolizumab)...
JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patientsAnimesh Pardanani
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 83:457-9. 2008..Our study also suggests that the natural history of a JAK2V617F-positive "occult" MPN might be different from that of a typical MPN...
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic valueMrinal M Patnaik
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Blood 119:569-72. 2012..In other words, when RARS and RCMD-RS were analyzed separately, there was no additional prognostic value from the presence or absence of SF3B1 mutations...
One thousand patients with primary myelofibrosis: the mayo clinic experienceAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 87:25-33. 2012..To share our decades of experience with primary myelofibrosis and underscore the importance of outcomes research studies in designing clinical trials and interpreting their results...
Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institutionRafael Santana-Davila
Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 32:407-11. 2008..We conclude that del(5q), although most prevalent in MDS, is seen across the spectrum of myeloid disorders including MPD and its occurrence in lymphoid disorders might signify, for the most part, an occult myeloid clone...
The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphomaYinlee Yoong
Division of Hematology, Department of Internal Medecine, Mayo Clinic, Rochester, MN 55909, USA
Leuk Lymphoma 46:1287-94. 2005..0001). Multivariate analysis demonstrated K-ALC recovery post-ASCT to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that the K-ALC post-ASCT is associated with clinical outcome in NHL...
Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring systemDavid Dingli
Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer 106:623-30. 2006..The new system displayed a stronger discriminative value, between risk categories, compared with currently existing prognostic models...
Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assayCody A Koch
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 127:34-9. 2004..86% test accuracy). The current study suggests that PRP serotonin concentration might be considered as one of the several biological markers that complement each other for the diagnosis of PV...
Eosinophilia: secondary, clonal and idiopathicAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Br J Haematol 133:468-92. 2006..The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment...
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsAnimesh D Pardanani
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Blood 108:3472-6. 2006..Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease...
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignanciesAnimesh Pardanani
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Blood 114:3769-72. 2009....
Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatmentDavid Dingli
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Intern Med 43:540-7. 2004..Among the novel agents tested, thalidomide seems the most promising although newer agents are on the horizon...
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Blood 102:3093-6. 2003..Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD...
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patientsAyalew Tefferi
Divisions of Hematology, Mayo Clinic, Rochester, MN, USA
Blood 118:4595-8. 2011..2, 95% confidence interval 1.6-3.1; P < .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches...
Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patientsBrijesh Arora
Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA
Br J Haematol 128:42-8. 2005..The current prospective study does not support an independent prognostic value for PB CD34 count in MMM...
Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasiaWilliam J Hogan
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Hematol Malig Rep 2:34-42. 2007....
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosisLuis F Porrata
Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Clin Cancer Res 11:1210-8. 2005..The relationship of ALC-15 with clinical outcomes in primary systemic amyloidosis is unknown...
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotypeAyalew Tefferi
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 85:14-7. 2010..We conclude that transfusion status in PMF downgrades or upgrades prognosis within specific IPSS categories; transfusion need is a marker of aggressive disease biology in PMF, as it is in myelodysplastic syndromes...
Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosisNaseema Gangat
Division of Hematology, Department of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota55905, USA
Am J Hematol 83:451-3. 2008..30%; P = 0.003). Multivariable analysis revealed that these associations were independent of other risk factors for thrombosis. High JAK2V617F allele burden clustered with pruritus (P = 0.002) but did not affect thrombosis rates...
Risk-based management of myelodysplastic syndromeDavid P Steensma
Mayo Clinic, Rochester, Minnesota, USA
Oncology (Williston Park) 21:43-54; discussion 57-8, 62. 2007..While many questions remain about the optimal use of newer agents, the long-standing perception of MDS as a syndrome where therapeutic nihilism is the only realistic approach is slowly beginning to change...
Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institutionAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 109:2083-8. 2007..Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups...
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factorsKen Hong Lim
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Blood 113:5727-36. 2009..The current study validates the prognostic relevance of the WHO subclassification of SM and provides additional information of value in terms of both risk stratification and interpretation of clinical presentation and laboratory results...
Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 yearsPankaj Malhotra
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 49:1724-30. 2008..All surviving patients displayed excellent performance status without ongoing chronic graft versus host disease. We conclude that ASCT is an effective salvage therapy for fludarabine-refractory CLL but late relapses can occur...
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Blood 104:1881-7. 2004..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasiaRuben A Mesa
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 101:2534-41. 2003..Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM...
Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapyMichelle A Elliott
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 88:237-43. 2012..Therapy-related APL is sensitive to standard therapy with no cases of resistance or relapse seen. The inferior OS of the t-APL was due to induction mortality, possibly reflecting prior therapy...
Molecular diagnosis of myeloproliferative neoplasmsMrinal M Patnaik
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Expert Rev Mol Diagn 9:481-92. 2009..In patients with clonal eosinophilic disorders and mast cell disease, the use of molecular diagnostics to identify novel mutations and gene rearrangements, has resulted in superior diagnostic and therapeutic strategies...
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasiaAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 104:1656-60. 2005..The current prospective study addresses this issue in the context of currently accepted independent prognostic variables...
Clinical, genetic, and therapeutic insights into systemic mast cell diseaseAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Curr Opin Hematol 11:58-64. 2004..The purpose of this review is to summarize current concepts and recent advances in the pathogenesis and treatment of adult mast cell disease...
Risk factors for leukemic transformation in patients with primary myelofibrosisJocelin Huang
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 112:2726-32. 2008..However, to the authors' knowledge, information regarding risk factors for leukemic transformation in primary myelofibrosis is limited...
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosisKebede Hussein
Divisions of Hematology, Hematopathology, Mayo Clinic, Rochester, MN, USA
Blood 115:496-9. 2010..37; 95% confidence interval, 0.24-0.58) cytogenetic risk categorization (P < .01). The ability to prognostically dissect a specific IPSS category has major therapeutic implications...
Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemiaAyalew Tefferi
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Blood 103:3547-8. 2004..However, quantifying neutrophil PRV-1 mRNA, while complementary to other tests, is not in itself sufficient for the diagnosis of PV...
Myeloproliferative neoplasms: contemporary diagnosis using histology and geneticsAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Nat Rev Clin Oncol 6:627-37. 2009..We discuss histologic, cytogenetic and molecular changes in MPN and illustrate their integration into practical diagnostic algorithms...
C-terminal nucleophosmin mutations are uncommon in chronic myeloid disordersJonathan S C Caudill
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 133:638-41. 2006..All other patients were NPM1-wild type in the region analysed. In conclusion, C-terminal NPM mutations are uncommon in chronic myeloid neoplasia, but if present may represent an evolving leukaemic clone...
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet countDavid P Steensma
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Haematologica 91:ECR57. 2006....
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survivalRakhee Vaidya
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Blood 117:5612-5. 2011..8 (1.7-130.8). The prognostic relevance of MK was not accounted for by the Dynamic International Prognostic Scoring System. We conclude that MK in primary myelofibrosis is associated with extremely poor overall and leukemia-free survival...
Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemiaYinlee Yoong
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 74:124-7. 2005..These results are contrary to previous reports that suggested inferior survival as well as poor response to alpha interferon therapy in CML patients carrying der(9) deletions...
Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcomeAndrew P Landstrom
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 48:2137-40. 2007..Multivariable analysis identified Ph mosaicism as a risk factor for shortened survival. Due to the small sample size, the current preliminary observations require validation in a larger group of patients...
Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasiaDavid P Steensma
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 74:47-53. 2005..In addition, it is unclear whether patients with MDS-associated acquired alpha thalassaemia (ATMDS), a special subgroup with a very high incidence of point mutations in the ATRX gene, have an especially high incidence of RUNX1 mutations...
Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasiaBrijesh Arora
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Haematologica 89:1454-8. 2004..The study also suggests either a megakaryocyte origin or a megakaryocyte effect for the putative angiogenic cytokine...
Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasiaMichelle A Elliot
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Eur J Haematol 68:175-9. 2002..Consistent with previous observations in animal models, our observations suggest the possibility that altered TPO regulation resulting in sustained ligand excess may have pathogenetic relevance in MMM...
Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasiaTerra L Reeder
Mayo Clinic, Rochester, MN 55905, USA
Blood 101:1981-3. 2003..The current study provides direct evidence for the clonal involvement of both B and T lymphocytes in MMM. A larger study is needed to clarify the relevance of the observed interpatient heterogeneity in clonal constitution...
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disordersAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 101:3391-7. 2003..Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy...
Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disordersAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 28:S47-52. 2004..These observations make it necessary to re-examine current disease classification and treatment algorithms in eosinophilic disorders...
Cytogenetic and molecular genetic aspects of essential thrombocythemiaDavid P Steensma
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn. 55905, USA
Acta Haematol 108:55-65. 2002..In the future, global analysis of gene expression patterns may help overcome diagnostic dilemmas, refine disease classification, and lead to an improved understanding of the pathogenesis of ET...
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disordersAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Blood 104:1931-9. 2004..Imatinib is considered investigational for the treatment of hematologic malignancies without a defined molecular drug target, such as polycythemia vera, myelofibrosis with myeloid metaplasia, and acute myeloid leukemia...
Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective studyAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:1169-75. 2002..In contrast, BM angiogenesis, reticulin fibrosis, and levels of MC mediators showed no prognostic relevance...
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatmentAyalew Tefferi
Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 80:390-402. 2005..These issues are discussed within the context of clinical practice...
Primer on medical genomics part II: Background principles and methods in molecular geneticsAyalew Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:785-808. 2002....
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research andRuben A Mesa
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 31:737-40. 2007....
Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell diseaseAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 27:739-42. 2003..In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia...
Bone marrow angiogenesis in systemic mast cell diseaseJin-Young Baek
Divisions of Hematopathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Hematother Stem Cell Res 11:139-46. 2002..We conclude that bone marrow angiogenesis characterizes a percentage of patients with SMCD and that the pathogenesis may not necessarily be linked to the mast cells themselves...
Pharmacotherapy of essential thrombocythemiaNaseema Gangat
Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA
Expert Opin Pharmacother 9:1679-85. 2008..Advanced age and a prior history of thrombosis are the major predictors of thrombotic complications...
Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasiaLeonardo N Faoro
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Eur J Haematol 74:117-20. 2005..CONCLUSION: This study confirmed relevant and frequently durable palliation of symptoms in about half the patients. 2-CdA is a reasonable palliative option in postsplenectomy patients with MMM who have problematic myeloproliferation...
Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosusY Nancy You
Department of Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Ann Surg 240:286-92. 2004..The overall PR or CR to splenectomy combined with medical therapy was 84%. CONCLUSION: Splenectomy should be considered safe and efficacious for thrombocytopenia associated with SLE...
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitroBenjamin M F Mow
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55901, USA
Blood 99:664-71. 2002..Collectively, these results identify adaphostin as a mechanistically distinct CML-selective agent that retains activity in STI571-resistant cell lines...
Clinical features in T-cell vs. natural killer-cell variants of large granular lymphocyte leukemiaMichelle A Neben
Division of Hematology and Internal Medicine; Division of Hematopathology, Mayo Clinic, Mayo Medical School, Rochester, MN 55905, USA
Eur J Haematol 71:263-5. 2003..04) and a higher frequency of palpable splenomegaly (P < 0.01). CONCLUSION: Overall disease progression and response to immunosuppressive therapy are similar between T-cell and natural killer-cell variants of LGLL...
KIT and mastocytosisKen Hong Lim
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Acta Haematol 119:194-8. 2008..In general, conventional therapy for SM is suboptimal, and efforts are under way to develop and employ small molecule drugs that target mutant KIT...
Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophiliaAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 27:883-5. 2003..The clinical implications of this finding are discussed...
Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the newAyalew Tefferi
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Semin Hematol 40:18-21. 2003..Optimal therapy for an individual patient requires a sound understanding of disease risk factors, as well as a full appreciation of the risk to benefit ratio for a specific treatment modality...
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cellsJoya Chandra
Division of Oncology Research, Guggenheim 1301, Mayo Clinic, 200 First St, SW, Rochester, MN 55901, USA
Blood 102:4512-9. 2003....
Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemiaAndrew P Landstrom
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Leuk Lymphoma 47:2055-61. 2006..0001 for each). Furthermore, we demonstrate that peripheral blood D-FISH can be used as a surrogate for cytogenetic studies in monitoring cytogenetic remission status...
The prognostic significance of trisomy 8 in patients with acute myeloid leukemiaMichelle A Elliott
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 43:583-6. 2002..The presence of +8 did not appear to adversely affect the outcome of patients with favorable karyotypes...
The rise and fall of red cell mass measurement in polycythemia veraAyalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Curr Hematol Rep 4:213-7. 2005....
Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemiaGrzegorz S Nowakowski
Department of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 128:490-2. 2005..Cytopenias occurred in all five 'mismatch' patients but not in two patients with 'match', suggesting that KIR/HLA-I mismatch may contribute to the suppression of haematopoiesis...
Agnogenic myeloid metaplasia with pleural extramedullary leukemic transformationHassan F Nadrous
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Leuk Lymphoma 45:815-8. 2004..He was hospitalized for neutropenic fever and was diagnosed to have pulmonary aspergillosis. He died of multisystem failure 8 1/2 months after being diagnosed with AMM...
Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell diseaseJin-Young Baek
Division of Hematopathology and Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 26:83-90. 2002..The results confirm the diagnostic value of Kit immunohistochemistry in MCD and suggest a biologically relevant heterogeneity in TGFbeta1R expression among patients with SMCD-HD...
Current management of polycythemia veraAyalew Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 43:1-7. 2002..The role of aspirin is being readdressed by an ongoing controlled study. Transformation of PV into either myelofibrosis with myeloid metaplasia or acute leukemia remains a major complication that may not be influenced by current therapy...
Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasiaBrijesh Arora
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 45:2373-86. 2004..In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM...
Suppressors of cytokine signaling and regulation of clonal erythropoiesisAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Leuk Lymphoma 48:7-8. 2007
Treatment of hypereosinophilic syndrome with imatinib mesilateGerald J Gleich
Department of Immunology, Allergic Diseases Research Laboratory, Mayo Clinic and Foundation, Rochester, MN, USA
Lancet 359:1577-8. 2002..All patients who responded stopped other treatments and reduced imatinib mesilate to 200 mg per week. This drug effectively controls eosinophilia in patients with hypereosinophilic syndrome and normal interleukin-5 concentrations...
Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipientsBekele Afessa
Department of Medicine, Divisions of Pulmonary and Critical Care Medicine and Hematology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Am J Respir Crit Care Med 166:1364-8. 2002..This study shows that survival rate of hematopoietic stem cell transplant recipients with diffuse alveolar hemorrhage is better than previously reported, and that early onset and autologous transplant are favorable prognostic indicators...
